Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Annals of Behavioral Medicine
Erschienen in: Annals of Behavioral Medicine 2/2011

01.04.2011 | Original Article

New Methods for Tobacco Dependence Treatment Research

verfasst von: Timothy B. Baker, Ph.D., Robin Mermelstein, Ph.D., Linda M. Collins, Ph.D., Megan E. Piper, Ph.D., Douglas E. Jorenby, Ph.D., Stevens S. Smith, Ph.D., Bruce A. Christiansen, Ph.D., Tanya R. Schlam, Ph.D., Jessica W. Cook, Ph.D., Michael C. Fiore, MD, MPH, MBA

Erschienen in: Annals of Behavioral Medicine | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Despite advances in tobacco dependence treatment in the past two decades, progress has been inconsistent and slow. This paper reviews pervasive methodological issues that may contribute to the lack of timely progress in tobacco treatment science including the lack of a dynamic model or framework of the cessation process, inefficient study designs, and the use of distal outcome measures that poorly index treatment effects. The authors then present a phase-based cessation framework that partitions the cessation process into four discrete phases based on current theories of cessation and empirical data. These phases include: (1) Motivation, (2) Precessation, (3) Cessation, and (4) Maintenance.

Discussion

Within this framework, it is possible to identify phase-specific challenges that a smoker would encounter while quitting smoking, intervention components that would address these phase-specific challenges, mechanisms via which such interventions would exert their effects, and optimal outcome measures linked to these phase-specific interventions. Investigation of phase-based interventions can be accelerated by using efficient study designs that would permit more timely development of an optimal smoking cessation treatment package.
Fußnoten
1
There is evidence that as abstinence continues there may be intrinsic processes that thwart lapsing or relapsing and that this results in a point at which relapse becomes relatively unlikely [28]. Thus, it is possible that with very long interventions, treatment will take the majority of individuals past this point and result in very durable effect sizes (e.g., [11, 47]).
 
2
Some smokers make quit attempts in an apparently spontaneous manner. They do not select a quit day nor formally state an intention to quit [52‐54]. The current model is designed to organize and assess interventions and intervention evaluations. Obviously, there would be little opportunity to organize Precessation interventions for the person who makes an unplanned quit attempt, and the framework would not, by itself, indicate the motivational factors that resulted in such a quit attempt. A theory such as the transtheoretical model would be more appropriate for that purpose.
 
3
Other bases could have been used for the demarcation of phases. For instance, the Transtheoretical model defines stages based upon both pragmatic considerations, such as a person’s willingness or attempt to quit, and upon patterns of change processes over time [51]. We also emphasize a pragmatic strategy, one based on clinically useful distinctions, in order to promote more general buy-in by diverse investigators, which might lead to greater adoption of a common framework and complementary research efforts.
 
Literatur
1.
Thornton M. The next front on the war on cancer. Wall Street Journal. 2009;Sect. A17.
2.
Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Rockville, MD: U.S. Department of Health and Human Services, U.S. Public Health Service; 2008.
3.
Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev. 2005(2):CD001292.PubMed
4.
Stead L, Perera R, Lancaster T. Telephone counselling for smoking cessation. Cochrane Database Syst Rev. 2006;3:CD002850.PubMed
5.
Biener L, Reimer RL, Wakefield M, Szczypka G, Rigotti NA, Connolly G. Impact of smoking cessation aids and mass media among recent quitters. Am J Prev Med. 2006;30(3):217–24.PubMedCrossRef
6.
Cokkinides VE, Ward E, Jemal A, Thun MJ. Under-use of smoking-cessation treatments: Results from the National Health Interview Survey, 2000. Am J Prev Med. 2005;28(1):119–22.PubMedCrossRef
7.
Solberg LI, Asche SE, Boyle R, McCarty MC, Thoele MJ. Smoking and cessation behaviors among young adults of various educational backgrounds. Am J Public Health. 2007;97(8):1421–6.PubMedCrossRef
8.
Fiore MC, Bailey WC, Cohen SJ. Smoking cessation: Clinical practice guideline No. 18. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research; 1996.
9.
Fiore MC, Bailey WC, Cohen SJ. Treating tobacco use and dependence: Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services, U.S. Public Health Service; 2000.
10.
Shiffman S. Smoking cessation treatment: Any progress? J Consult Clin Psychol. 1993;61(5):718–22.PubMedCrossRef
11.
Hall SM, Humfleet GL, Reus VI, Munoz RF, Cullen J. Extended nortriptyline and psychological treatment for cigarette smoking. Am J Psychiatry. 2004;161(11):2100–7.PubMedCrossRef
12.
Carroll KM. Relapse prevention as a psychosocial treatment: A review of controlled clinical trials. Exp Clin Psychopharmacol. 1996;4(1):46–54.CrossRef
13.
Lichtenstein E, Hollis J. Patient referral to a smoking cessation program: Who follows through? J Fam Pract. 1992;34(6):739–44.PubMed
14.
Niaura R, Abrams DB. Smoking cessation: Progress, priorities, and prospectus. J Consult Clin Psychol. 2002;70(3):494–509.PubMedCrossRef
15.
Piasecki TM, Baker TB. Any further progress in smoking cessation treatment? Nicotine Tob Res. 2001;3(4):311–23.PubMedCrossRef
16.
Velicer WF, Rossi JS, Diclemente CC, Prochaska JO. A criterion measurement model for health behavior change. Addict Behav. 1996;21(5):555–84.PubMedCrossRef
17.
Friend K, Levy DT. Smoking treatment interventions and policies to promote their use: A critical review. Nicotine Tob Res. 2001;3(4):299–310.PubMedCrossRef
18.
Hollis JF, Bills R, Whitlock E, Stevens VJ, Mullooly J, Lichtenstein E. Implementing tobacco interventions in the real world of managed care. Tob Control. 2000;9(Suppl 1):i18–24.PubMedCrossRef
19.
Collins LM, Baker TB, Mermelstein RJ, et al. The Multiphase Optimization Strategy for engineering effective tobacco use interventions. Ann Behav Med. 2011 (in press).
20.
Strecher VJ, McClure J, Alexander G, et al. Web-based smoking cessation components and tailoring depth: Results of a randomized trial. Am J Prev Med. 2008;34:373–81.PubMedCrossRef
21.
Collins LM, Murphy SA, Nair VN, Strecher VJ. A strategy for optimizing and evaluating behavioral interventions. Ann Behav Med. 2005;30(1):65–73.PubMedCrossRef
22.
Glasgow RE, Lichtenstein E, Marcus AC. Why don’t we see more translation of health promotion research to practice? Rethinking the efficacy-to-effectiveness transition. Am J Public Health. 2003;93(8):1261–7.PubMedCrossRef
23.
Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA. 2006;296:47–55.PubMedCrossRef
24.
Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. JAMA. 2006;296(1):56–63.PubMedCrossRef
25.
Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction. 2004;99(1):29–38.PubMedCrossRef
26.
Kenford SL, Fiore MC, Jorenby DE, Smith SS, Wetter D, Baker TB. Predicting smoking cessation. Who will quit with and without the nicotine patch. JAMA. 1994;271(8):589–94.PubMedCrossRef
27.
Hughes JR, Peters EN, Naud S. Relapse to smoking after 1 year of abstinence: A meta-analysis. Addict Behav. 2008;33(12):1516–20.PubMedCrossRef
28.
Kirshenbaum AP, Olsen DM, Bickel WK. A quantitative review of the ubiquitous relapse curve. J Subst Abuse Treat. 2009;36(1):8–17.PubMedCrossRef
29.
Carey MP, Snel DL, Carey KB, Richards CS. Self-initiated smoking cessation: A review of the empirical literature from a stress and coping perspective. Cogn Ther Res. 1989;13:323–41.CrossRef
30.
Carey MP, Kalra DL, Carey KB, Halperin S, Richards CS. Stress and unaided smoking cessation: A prospective investigation. J Consult Clin Psychol. 1993;61(5):831–8.PubMedCrossRef
31.
Weaver K, Campbell R, Mermelstein R, Wakschlag L. Pregnancy smoking in context: The influence of multiple levels of stress. Nicotine Tob Res. 2008;10(6):1065–73.PubMedCrossRef
32.
Derby CA, Lasater TM, Vass K, Gonzalez S, Carleton RA. Characteristics of smokers who attempt to quit and of those who recently succeeded. Am J Prev Med. 1994;10(6):327–34.PubMed
33.
Homish GG, Leonard KE. Spousal influence on smoking behaviors in a US community sample of newly married couples. Soc Sci Med. 2005;61(12):2557–67.PubMedCrossRef
34.
Mermelstein R, Cohen S, Lichtenstein E, Baer JS, Kamarck T. Social support and smoking cessation and maintenance. J Consult Clin Psychol. 1986;54(4):447–53.PubMedCrossRef
35.
36.
Shiffman S. Maintence and relapse: Coping with temptation. In: Nirenberg TD, ed. Advances in the treatment of addictive behaviors. Norwood, NJ: Ablex; 1987:353–85.
37.
Dollar KM, Homish GG, Kozlowski LT, Leonard KE. Spousal and alcohol-related predictors of smoking cessation: A longitudinal study in a community sample of married couples. Am J Public Health. 2009;99(2):231–3.PubMedCrossRef
38.
Krall EA, Garvey AJ, Garcia RI. Smoking relapse after 2 years of abstinence: Findings from the VA Normative Aging Study. Nicotine Tob Res. 2002;4:95–100.PubMedCrossRef
39.
Bolt DM, Piper ME, McCarthy DE, et al. The Wisconsin Predicting Patients’ Relapse questionnaire. Nicotine Tob Res. 2009;11(5):481–92.PubMedCrossRef
40.
Lee CW, Kahende J. Factors associated with successful smoking cessation in the United States, 2000. Am J Public Health. 2007;97(8):1503–9.PubMedCrossRef
41.
Piasecki TM, Fiore MC, McCarthy DE, Baker TB. Have we lost our way? The need for dynamic formulations of smoking relapse proneness. Addiction. 2002;97(9):1093–108.PubMedCrossRef
42.
43.
Hughes JR, Callas PW. Errors in interpreting abstinence curves in studies of smoking cessation. Nicotine Tob Res. 2006;8(1):7–12.PubMedCrossRef
44.
Medioni J, Berlin I, Mallet A. Increased risk of relapse after stopping nicotine replacement therapies: A mathematical modelling approach. Addiction. 2005;100(2):247–54.PubMedCrossRef
45.
Shiffman S, Scharf DM, Shadel WG, et al. Analyzing milestones in smoking cessation: Illustration in a nicotine patch trial in adult smokers. J Consult Clin Psychol. 2006;74(2):276–85.PubMedCrossRef
46.
Japuntich SJ, Piper ME, Leventhal AM, Bolt DM, Baker TB. The effect of five smoking cessation pharmacotherapies on smoking cessation milestones. J Consult Clin Psychol. 2011 (in press).
47.
Hall SM, Humfleet GL, Munoz RF, Reus VI, Robbins JA, Prochaska JJ. Extended treatment of older cigarette smokers. Addiction. 2009;104(6):1043–52.PubMedCrossRef
48.
Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: Toward an integrative model of change. J Consult Clin Psychol. 1983;51(3):390–5.PubMedCrossRef
49.
Prochaska JO, DiClemente CC. Stages of change in the modification of problem behaviors. Newbury Park, CA: Sage; 1992.
50.
Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. Am J Health Promot. 1997;12(1):38–48.PubMed
51.
Prochaska JO, Wright JA, Velicer WF. Evaluating theories of health behavior change: A hierarchy of criteria applied to the Transtheoretical Model. Appl Psychol. 2008;57(4):561–88.CrossRef
52.
Nielsen A, Hannibal CG, Lindekilde BE, et al. Maternal smoking predicts the risk of spontaneous abortion. Acta Obstet Gynecol Scand. 2006;85(9):1057–65.PubMedCrossRef
53.
Ockene J, Ma Y, Zapka J, Pbert L, Valentine Goins K, Stoddard A. Spontaneous cessation of smoking and alcohol use among low-income pregnant women. Am J Prev Med. 2002;23(3):150–9.PubMedCrossRef
54.
Bauld L, Chesterman J, Ferguson J, Judge K. A comparison of the effectiveness of group-based and pharmacy-led smoking cessation treatment in Glasgow. Addiction. 2009;104(2):308–16.PubMedCrossRef
55.
Piasecki TM, Fiore MC, Baker TB. Profiles in discouragement: Two studies of variability in the time course of smoking withdrawal symptoms. J Abnorm Psychol. 1998;107(2):238–51.PubMedCrossRef
56.
Piasecki TM, Niaura R, Shadel WG, et al. Smoking withdrawal dynamics in unaided quitters. J Abnorm Psychol. 2000;109(1):74–86.PubMedCrossRef
57.
Piasecki TM, Jorenby DE, Smith SS, Fiore MC, Baker TB. Smoking withdrawal dynamics: I. Abstinence distress in lapsers and abstainers. J Abnorm Psychol. 2003;112(1):3–13.PubMedCrossRef
58.
McCarthy DE, Piasecki TM, Fiore MC, Baker TB. Life before and after quitting smoking: An electronic diary study. J Abnorm Psychol. 2006;115(3):454–66.PubMedCrossRef
59.
Hughes JR. Effects of abstinence from tobacco: Etiology, animal models, epidemiology, and significance: A subjective review. Nicotine Tob Res. 2007;9(3):329–39.PubMedCrossRef
60.
Welsch SK, Smith SS, Wetter DW, Jorenby DE, Fiore MC, Baker TB. Development and validation of the Wisconsin Smoking Withdrawal Scale. Exp Clin Psychopharmacol. 1999;7(4):354–61.PubMedCrossRef
61.
McCarthy DE, Piasecki TM, Lawrence DL, Jorenby DE, Shiffman S, Baker TB. Psychological mediators of bupropion sustained-release treatment for smoking cessation. Addiction. 2008;103(9):1521–33.PubMedCrossRef
62.
Piper ME, Federman EB, McCarthy DE, et al. Mediators of bupropion treatment effects. In: 14th Annual Meeting for the Society for Research in Nicotine and Tobacco; 2008 Feb 27–Mar 1; Portland, OR; 2008.
63.
Etter JF, Perneger TV, Ronchi A. Distributions of smokers by stage: International comparison and association with smoking prevalence. Prev Med. 1997;26(4):580–5.PubMedCrossRef
64.
Baker TB, Piper ME, McCarthy DE, Majeskie MR, Fiore MC. Addiction motivation reformulated: An affective processing model of negative reinforcement. Psychol Rev. 2004;111(1):33–51.PubMedCrossRef
65.
Curry S, Wagner EH, Grothaus LC. Intrinsic and extrinsic motivation for smoking cessation. J Consult Clin Psychol. 1990;58(3):310–6.PubMedCrossRef
66.
Curry SJ, McBride C, Grothaus L, Lando H, Pirie P. Motivation for smoking cessation among pregnant women. Psychol Addict Behav. 2001;15(2):126–32.PubMedCrossRef
67.
Hatsukami D, Baker, TB. Nicotine addiction: Past and present. In: How tobacco causes disease: The biology and behavioral bases for tobacco-attributable disease: Report of the Surgeon General, U. S. Government Priority Office: Washington D.C. 2011 (in press).
68.
McBride CM, Curry SJ, Stephens RS, Wells EA, Roffman RA, Hawkins JD. Intrinsic and extrinsic motivation for change in cigarette smokers, marijuana smokers, and cocaine users. Psychol Addict Behav. 1994;8:243–50.CrossRef
69.
Williams GC, Gagne M, Ryan RM, Deci EL. Facilitating autonomous motivation for smoking cessation. Health Psychol. 2002;21(1):40–50.PubMedCrossRef
70.
Williams GC, McGregor HA, Sharp D, et al. Testing a self-determination theory intervention for motivating tobacco cessation: Supporting autonomy and competence in a clinical trial. Health Psychol. 2006;25(1):91–101.PubMedCrossRef
71.
Hughes JR, Carpenter MJ. Does smoking reduction increase future cessation and decrease disease risk? A qualitative review. Nicotine Tob Res. 2006;8(6):739–49.PubMedCrossRef
72.
Rose JE, Herskovic JE, Trilling Y, Jarvik ME. Transdermal nicotine reduces cigarette craving and nicotine preference. Clin Pharmacol Ther. 1985;38(4):450–6.PubMedCrossRef
73.
Rose JE. New findings on nicotine addiction and treatment. Nebr Symp Motiv. 2009;55:131–41.PubMed
74.
LeSage MG, Keyler DE, Shoeman D, Raphael D, Collins G, Pentel PR. Continuous nicotine infusion reduces nicotine self-administration in rats with 23-h/day access to nicotine. Pharmacol Biochem Behav. 2002;72(1–2):279–89.PubMedCrossRef
75.
Cinciripini PM, Lapitsky L, Seay S, Wallfisch A, Kitchens K, Van Vunakis H. The effects of smoking schedules on cessation outcome: Can we improve on common methods of gradual and abrupt nicotine withdrawal? J Consult Clin Psychol. 1995;63(3):388–99.PubMedCrossRef
76.
Cinciripini PM, Wetter DW, McClure JB. Scheduled reduced smoking: Effects on smoking abstinence and potential mechanisms of action. Addict Behav. 1997;22(6):759–67.PubMedCrossRef
77.
Hughes JR, Carpenter MJ. The feasibility of smoking reduction: An update. Addiction. 2005;100(8):1074–89.PubMedCrossRef
78.
Stead LF, Lancaster T. Interventions to reduce harm from continued tobacco use. Cochrane Database Syst Rev. 2007(3):CD005231.PubMed
79.
Williams G, Minicucci D, Kouides R, et al. Self-determination, smoking, diet and health. Health Educ Res. 2002;17(5):512–21.PubMedCrossRef
80.
Rose JE, Behm FM, Westman EC, Kukovich P. Precessation treatment with nicotine skin patch facilitates smoking cessation. Nicotine Tob Res. 2006;8(1):89–101.PubMedCrossRef
81.
Etter JF, Laszlo E, Zellweger JP, Perrot C, Perneger TV. Nicotine replacement to reduce cigarette consumption in smokers who are unwilling to quit: A randomized trial. J Clin Psychopharmacol. 2002;22(5):487–95.PubMedCrossRef
82.
McCarthy DE, Bolt DM, Baker TB. The importance of how: A call for mechanistic research in tobacco dependence treatment studies. In: Treat T, Bootzin RI, Baker TB, eds. Psychological clinical science: Recent advances in theory and practice: Integrative perspectives in honor of Richard M McFall. New York: Lawrence Erlbaum Associates; 2007:133–63.
83.
Piper ME, Federmen EB, McCarthy DE, et al. Using mediational models to explore the nature of tobacco motivation and tobacco treatment effects. J Abnorm Psychol. 2008;117(1):94–105.PubMedCrossRef
84.
Schuurmans MM, Diacon AH, van Biljon X, Bolliger CT. Effect of pre-treatment with nicotine patch on withdrawal symptoms and abstinence rates in smokers subsequently quitting with the nicotine patch: A randomized controlled trial. Addiction. 2004;99(5):634–40.PubMedCrossRef
85.
Collins LM, Murphy SA, Strecher V. The Multiphase Optimization Strategy (MOST) and the Sequential Multiple Assignment Randomized Trial (SMART): New methods for more potent eHealth interventions. Am J Prev Med. 2007;32(5 Suppl):S112–8.PubMedCrossRef
86.
Abrams DB, Monti PM, Carey KB, Pinto RP, Jacobus SI. Reactivity to smoking cues and relapse: Two studies of discriminant validity. Behav Res Ther. 1988;26(3):225–33.PubMedCrossRef
87.
Ferguson SG, Shiffman S. The relevance and treatment of cue-induced cravings in tobacco dependence. J Subst Abuse Treat. 2009;36(3):235–43.PubMedCrossRef
88.
Shiffman S, Gwaltney CJ, Balabanis MH, et al. Immediate antecedents of cigarette smoking: An analysis from ecological momentary assessment. J Abnorm Psychol. 2002;111(4):531–45.PubMedCrossRef
89.
Garvey AJ, Bliss RE, Hitchcock JL, Heinold JW, Rosner B. Predictors of smoking relapse among self-quitters: A report from the Normative Aging Study. Addict Behav. 1992;17(4):367–77.PubMedCrossRef
90.
Ferguson SG, Shiffman S, Gwaltney CJ. Does reducing withdrawal severity mediate nicotine patch efficacy? A randomized clinical trial. J Consult Clin Psychol. 2006;74(6):1153–61.PubMedCrossRef
91.
Rose JE, Uhl GR. Disrupting nicotine reinforcement: From cigarette to brain. In: Uhl GR, ed. Addiction reviews 2008 Annals of the New York Academy of Sciences. Malden: Blackwell Publishing; 2008:233–56.
92.
Bullen C, Whittaker R, Walker N, Wallace-Bell M. Pre-quitting nicotine replacement therapy: Findings from a pilot study. Tobacco Induced Diseases. 2006;3(2):35–40.PubMed
93.
Lam TH, Abdullah AS, Chan SS, Hedley AJ. Adherence to nicotine replacement therapy versus quitting smoking among Chinese smokers: A preliminary investigation. Psychopharmacology (Berl). 2005;177(4):400–8.CrossRef
94.
Waldroup WM, Gifford EV, Kalra P. Adherence to smoking cessation treatments. In: O’Donohue WT, R.Eric, eds. Promoting treatment adherence: A practical handbook for health care providers. Thousand Oaks, CA: Sage Publications, Inc.; 2006:235–52.
95.
Donny EC, Houtsmuller E, Stitzer ML. Smoking in the absence of nicotine: Behavioral, subjective and physiological effects over 11 days. Addiction. 2007;102(2):324–34.PubMedCrossRef
96.
Donny EC, Jones M. Prolonged exposure to denicotinized cigarettes with or without transdermal nicotine. Drug Alcohol Depend. 2009;104(1–2):23–33.PubMedCrossRef
97.
Droungas A, Ehrman RN, Childress AR, O’Brien CP. Effect of smoking cues and cigarette availability on craving and smoking behavior. Addict Behav. 1995;20(5):657–73.PubMedCrossRef
98.
Rose JE, George TP. Nicotine replacement therapies and other nicotinic strategies. In: George TP, ed. Medication treatments for nicotine dependence. Boca Raton, FL: CRC Press; 2007:63–74.
99.
Farkas AJ. When does cigarette fading increase the likelihood of future cessation? Ann Behav Med. 1999;21(1):71–6.PubMedCrossRef
100.
Juliano LM, Brandon TH. Reactivity to instructed smoking availability and environmental cues: Evidence with urge and reaction time. Exp Clin Psychopharmacol. 1998;6(1):45–53.PubMedCrossRef
101.
Levy DT, Romano E, Mumford E. The relationship of smoking cessation to sociodemographic characteristics, smoking intensity, and tobacco control policies. Nicotine Tob Res. 2005;7(3):387–96.PubMedCrossRef
102.
Nides MA, Rakos RF, Gonzales D, Murray RP, Tashkin DP, Bjornson-Benson WM. Predictors of initial smoking cessation and relapse through the first 2 years of the Lung Health Study. J Consult Clin Psychol. 1995;63(1):60–9.PubMedCrossRef
103.
McCarthy DE, Gloria R, Piper ME, Baker TB. A pilot study to test the feasibility of pre-cessation withdrawal exposure and rapid puffing among adult smokers motivated to quit. In: 15th Annual Meeting of the Society for Research on Nicotine & Tobacco; 2009 Apr; Dublin, Ireland; 2009
104.
Piper ME, Federman EB, McCarthy DE, et al. Efficacy of bupropion alone and in combination with nicotine gum. Nicotine Tob Res. 2007;9(9):947–54.PubMedCrossRef
105.
Piper ME, Smith SS, Schlam TR, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry. 2009;66(11):1253–62.PubMedCrossRef
106.
Westman EC, Behm FM, Simel DL, Rose JE. Smoking behavior on the first day of a quit attempt predicts long-term abstinence. Arch Intern Med. 1997;157(3):335–40.PubMedCrossRef
107.
Perkins KA, Stitzer M, Lerman C. Medication screening for smoking cessation: A proposal for new methodologies. Psychopharmacology (Berl). 2006;184(3–4):628–36.CrossRef
108.
Brandon TH, Tiffany ST, Obremski KM, Baker TB. Postcessation cigarette use: The process of relapse. Addict Behav. 1990;15(2):105–14.PubMedCrossRef
109.
Shiffman S, Balbanis M. Do drinking and smoking go together? Alcohol Health Res World. 1996;20(2):107–10.
110.
Curtin JJ, McCarthy DE, Piper ME, Baker TB. Implicit and explicit drug motivational processes: A model of boundary conditions. In: Weirs RW, Stacy AW, eds. Handbook of implicit cognition and addiction. Thousand Oaks, CA: Sage; 2006:233–50.
111.
Gloria R, Angelos L, Schaefer HS, et al. An fMRI investigation of the impact of withdrawal on regional brain activity during nicotine anticipation. Psychophysiology. 2009;46:681–93.PubMedCrossRef
112.
Zinser MC, Fiore MC, Davidson RJ, Baker TB. Manipulating smoking motivation: Impact on an electrophysiological index of approach motivation. J Abnorm Psychol. 1999;108(2):240–54.PubMedCrossRef
113.
Brandon TH, Meade CD, Herzog TA, Chirikos TN, Webb MS, Cantor AB. Efficacy and cost-effectiveness of a minimal intervention to prevent smoking relapse: Dismantling the effects of amount of content versus contact. J Consult Clin Psychol. 2004;72(5):797–808.PubMedCrossRef
114.
Shiffman S, Paty JA, Gwaltney CJ, Dang Q. Immediate antecedents of unrestricted smoking patterns. J Abnorm Psychol. 2004;113(1):166–71.CrossRef
115.
Chaudhri N, Caggiula AR, Donny EC, Palmatier MI, Liu X, Sved AF. Complex interactions between nicotine and nonpharmacological stimuli reveal multiple roles for nicotine in reinforcement. Psychopharmacology (Berl). 2006;184(3–4):353–66.CrossRef
116.
Kenny PJ, Markou A. Conditioned nicotine withdrawal profoundly decreases the activity of brain reward systems. J Neurosci. 2005;25(26):6208–12.PubMedCrossRef
117.
Gwaltney CJ, Shiffman S, Balabanis MH, Paty JA. Dynamic self-efficacy and outcome expectancies: Prediction of smoking lapse and relapse. J Abnorm Psychol. 2005;114(4):661–75.PubMedCrossRef
118.
Brandon TH, Zelman DC, Baker TB. Effects of maintenance sessions on smoking relapse: Delaying the inevitable? J Consult Clin Psychol. 1987;55(5):780–2.PubMedCrossRef
119.
Helgason AR, Tomson T, Lund KE, Galanti R, Ahnve S, Gilljam H. Factors related to abstinence in a telephone helpline for smoking cessation. Eur J Public Health. 2004;14(3):306–10.PubMedCrossRef
120.
Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR. Effect of maintenance therapy with varenicline on smoking cessation: A randomized controlled trial. JAMA. 2006;296(1):64–71.PubMedCrossRef
121.
Schmitz JM, Sayre SL, Stotts AL, Rothfleisch J, Mooney ME. Medication compliance during a smoking cessation clinical trial: A brief intervention using MEMS feedback. J Behav Med. 2005;28(2):139–47.PubMedCrossRef
122.
Lando HA, Valanis BG, Lichtenstein E, et al. Promoting smoking abstinence in pregnant and postpartum patients: A comparison of 2 approaches. Am J Manag Care. 2001;7(7):685–93.PubMed
123.
Hall SM, Munoz RF, Reus VI. Cognitive-behavioral intervention increases abstinence rates for depressive-history smokers. J Consult Clin Psychol. 1994;62(1):141–6.PubMedCrossRef
124.
Haynes RB, Yao X, Degani A, Kripalani S, Garg A, McDonald HP. Interventions to enhance medication adherence. Cochrane Database Syst Rev. 2005(4):CD000011.PubMed
125.
Grabowski J, O’Brien CP, Greenstein R, Ternes J, Long M, Steinberg-Donato S. Effects of contingent payment on compliance with a naltrexone regimen. Am J Drug Alcohol Abuse. 1979;6(3):355–65.PubMedCrossRef
126.
Elixhauser A, Eisen SA, Romeis JC, Homan SM. The effects of monitoring and feedback on compliance. Med Care. 1990;28(10):882–93.PubMedCrossRef
127.
Covey LS, Glassman AH, Jiang H, et al. A randomized trial of bupropion and/or nicotine gum as maintenance treatment for preventing smoking relapse. Addiction. 2007;102(8):1292–302.PubMedCrossRef
128.
Hays JT, Hurt RD, Rigotti NA, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. A randomized, controlled trial. Ann Intern Med. 2001;135(6):423–33.PubMed
129.
Horst WD, Klein MW, Williams D, Werder SF. Extended use of nicotine replacement therapy to maintain smoking cessation in persons with schizophrenia. Neuropsychiatric Dis Treat. 2005;1(4):349–55.
Metadaten
Titel
New Methods for Tobacco Dependence Treatment Research
verfasst von
Timothy B. Baker, Ph.D.
Robin Mermelstein, Ph.D.
Linda M. Collins, Ph.D.
Megan E. Piper, Ph.D.
Douglas E. Jorenby, Ph.D.
Stevens S. Smith, Ph.D.
Bruce A. Christiansen, Ph.D.
Tanya R. Schlam, Ph.D.
Jessica W. Cook, Ph.D.
Michael C. Fiore, MD, MPH, MBA
Publikationsdatum
01.04.2011
Verlag
Springer-Verlag
Erschienen in
Annals of Behavioral Medicine / Ausgabe 2/2011
Print ISSN: 0883-6612
Elektronische ISSN: 1532-4796
DOI
https://doi.org/10.1007/s12160-010-9252-y

Weitere Artikel der Ausgabe 2/2011

Annals of Behavioral Medicine 2/2011 Zur Ausgabe

Original Article

Directive and Nondirective E-Coach Support for Weight Loss in Overweight Adults

Original Article

Heart Disease Occurs in a Biological, Psychological, and Social Matrix: Cardiac Risk Factors, Symptom Presentation, and Recovery as Illustrative Examples

Original Article

Exploring the Intergenerational Transmission of Illness Behavior: From Observations to Experimental Intervention

Original Article

Self-regulation of Cerebral Blood Flow by Means of Transcranial Doppler Sonography Biofeedback

Original Article

The Multiphase Optimization Strategy for Engineering Effective Tobacco Use Interventions

Original Article

The Effect of Telephone-Administered Cognitive–Behavioral Therapy on Quality of Life among Patients with Multiple Sclerosis

Neu in den Fachgebieten Neurologie und Psychiatrie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Bildnachweise